-
J Pathology | Prof. Guoliang Yang and Prof. Xianbin Su Reveal the Molecular Landscape and Cellular Origins of Bladder Squamous Cell Carcinoma
Squamous cell carcinoma (SCC) of the bladder is a rare but highly aggressive malignancy associated with poor clinical outcomes and limited responsiveness to conventional therapies. Recently, Professor Guoliang Yang’s team from Renji Hospital, Shanghai Jiao Tong University School of Medicine, together with Professor Xianbin Su’s group from the Institute of Systems Biomedicine at Shanghai Jiao…
-
4th Urologic Oncology Clinical Research Conference | Professor Xinan Sheng: Driving Innovation in Urologic Oncology Through Unmet Clinical Needs
From the rapid evolution of systemic therapies to the emergence of ADCs, TCEs, and novel immunotherapeutic approaches, Professor Sheng shared his perspective on how Chinese clinical research is increasingly shaping…
-
CSCO Guideline Preview | Professor Hao Zeng Interprets the 2026 CSCO Prostate Cancer Guidelines: Advancing Precision Oncology for Chinese Patients
As one of the most common malignancies affecting men worldwide, prostate cancer requires continuously evolving diagnostic and therapeutic strategies. With rapid advances in precision medicine and the growing body of high-quality clinical evidence generated from Chinese patient populations, the 2026 CSCO Guidelines for Prostate Cancer introduce major updates aimed at better addressing the biological characteristics…
-
AOT 2026 | Professor Xiaodong Mo: Clinical Positioning and Key Decision-Making Considerations for Allogeneic Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphoma
To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the…
-
ZUCCS’16 | A Global Invitation to Advance Colorectal Cancer Care
Globally, colorectal cancer is the third most commonly diagnosed malignancy and the second leading cause of cancer-related death, placing a substantial burden on public health worldwide. Owing to its large population base, China accounts for 28.76% of global colorectal cancer incidence and 30.60% of related deaths, making it a major driving force in advancing colorectal…
-
CACA | Professor Gang Zhu: AI-Powered Holographic Imaging Advances Organ Function Preservation in Urologic Oncology Surgery
As part of the 2026 Chinese Guidelines for Holistic Integrative Oncology Management, the Chinese Guidelines for Holistic Integrative Oncology Management — Holographic Imaging Technology was officially released as the world’s first guideline dedicated to this field.
-
CURC & ARUF | Professor Tao Xu: New Perspectives on Endocrine Therapy for mHSPC — Evidence Review and Clinical Practice Centered on Enzalutamide
Prostate cancer is one of the most common malignant tumors of the male genitourinary system in China. Among these patients, metastatic hormone-sensitive prostate cancer (mHSPC) carries a particularly poor prognosis and remains a major clinical challenge. In recent years, novel hormonal therapies (NHTs), represented by enzalutamide, have continuously reshaped the treatment landscape of mHSPC. With…
-
4th Clinical Research Conference on Urologic Oncology | Breaking Through the Post-PD-1 Era: Professor Xieqiao Yan Interprets the Latest Advances in Kidney Cancer Research from ASCO GU 2026
At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Professor Xieqiao Yan from Peking University Cancer Hospital delivered a comprehensive presentation on the latest advances in kidney cancer therapy. His report focused on emerging clinical evidence surrounding the HIF-2α inhibitor belzutifan, particularly its evolving role in advanced clear cell renal cell…
Connecting Medical Expertise through Media